🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥 #CONFIDENCE in NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 nejm.org/doi/full/10.10…

More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.

👇👇👇 #AHA25 abstract deadline through Monday 10 AM ET!

#NUDGECKD in Circulation #ERA25 by Kristoffer Grundtvig Skaarup & Tor Biering-Sørensen, MD, MSc, MPH, PhD Nationwide 2x2 Pragmatic Implementation Mega-Trial 👥 n=22,617 🇩🇰 adults w #CKD 🥼n=1540 General practitioners Electronic nudges did not improve uptake of #RASi or #SGLT2i versus usual care ahajournals.org/doi/10.1161/CI…

AHA Members - tell your mentees to look for Council travel awards to #AHA25. Awards application deadline is 7pm ET TOMORROW! Chiadi Ndumele Janani Rangaswami Sadiya Khan Jacqueline Tamis-Holland Leslie L Davis, PhD, NP, FAAN Vanessa Blumer, MD, FACC Nosheen Reza, MD, MS

Combination therapy as a new standard of care in CKD - multiple trials testing new therapies in combo with SGLT2i - ARCTIC/PACIFIC trials: Baxdrostat/dapa vs. dapa - EASi-KIDNEY: Vicadrostat/empa vs. empa - ZENITH-HP: Zibotentan/dapa vs. dapa doi.org/10.1093/ndt/gf… #ERA25

🫘✨Combination therapy and pillars of care for CKD academic.oup.com/ndt/article/40… NDT Hans-Joachim Anders

📣 Medical students and residents are the future of medicine. Your voice matters. NYACP and @acpimphysicians can help you speak up and lead. #MedTwitter #ACPAdvocacy #FutureOfMedicine Tamara Goldberg

Many congrats Joshua Neumiller ! So proud of you and your leadership Katherine Tuttle Wendy St. Peter #CKM

Encouraging all residents, students, fellow, faculty to apply for AHA Science Kidney in Cardiovascular Disease Education contest. Thank you Matthew Sparks, MD for the write up. Janani Rangaswami Leslie Gewin Dr. Michelle Gumz

Kidney Dysfunction in Heart Failure: Core Curriculum 2025 - American Journal of Kidney Diseases ajkd.org/article/S0272-…

Panel examines benefits and barriers in therapies for CKD and diabetes - ADA Meeting News adameetingnews.org/panel-examines…

Looking forward to this fantastic webinar from the Kidney in Cardiovascular Disease!! Outstanding speakers! See below for details on registration! Janani Rangaswami Alexander Staruschenko Laboratory of Vivek Bhalla, MD- Stanford Dr. Heddwen Brooks, PhD, AJP-Renal Editor-in-Chief Council on Hypertension 👇🏽👇🏽👇🏽

It was wonderful to visit The George Institute for Global Health and Royal North Shore hospital and meet with Brendon Neuen and colleagues ! Enjoyed our discussions on #Cardiorenal Syndrome, decongestion and #GDMT, and beyond !

Absolutely delighted to host Prof Janani Rangaswami in Sydney this week - great talks and discussions with our faculty, nephrology trainees, and overseas visiting fellows from across the region - a few more pics from me! The George Institute for Global Health Northern Sydney Local Health District NORTH Foundation

This Core Curriculum explores commonly implicated pathophysiological mechanisms in kidney dysfunction in heart failure and discuss principles behind effective decongestion and assessment of adequacy of natriuresis: bit.ly/434spfa (FREE) Kevin Bryan Lo A. Janakiraman Janani Rangaswami

.Kidney in Cardiovascular Disease friends! Come gather in Baltimore for #Hypertension25! Don't miss out on the opportunity to gain cross-disciplinary connections and learn more about empowering hearts and uniting against #Hypertension this September Register: bit.ly/Hypertension25 #AHAScience

Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review Early diagnosis and intervention are important to slow CKD progression and reduce HF events. Shared therapeutic targets for CKD and HF include the renin–angiotensin

SGLT2i in CKD: impact beyond kidneys 🔻 15% all-cause hospitalizations ✅ Consistent across eGFR, UACR & diabetes 🏥 ~36 fewer hospitalizations per 1000 pt-years Large absolute gains for patients & health systems. Meta-analysis in ASN Publications: 🔗 journals.lww.com/cjasn/abstract…

New episode this week! We discuss pragmatic trial infrastructure in Denmark, implementation science in nephrology and how new approaches to recruitment can improve access, equity and representation in trials #kidneycompass